INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Up 144.7% in June

INVO Bioscience, Inc. (NASDAQ:INVO) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 75,600 shares, a growth of 144.7% from the May 31st total of 30,900 shares. Based on an average daily trading volume, of 3,800,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.0% of the shares of the company are sold short.

Institutional Investors Weigh In On INVO Bioscience

An institutional investor recently bought a new position in INVO Bioscience stock. Sabby Management LLC acquired a new stake in INVO Bioscience, Inc. (NASDAQ:INVO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 231,023 shares of the company’s stock, valued at approximately $183,000. INVO Bioscience accounts for approximately 0.1% of Sabby Management LLC’s holdings, making the stock its 29th biggest holding. Sabby Management LLC owned about 9.43% of INVO Bioscience as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

INVO Bioscience Stock Performance

Shares of INVO traded down $0.03 during mid-day trading on Friday, hitting $0.84. 19,222 shares of the company’s stock were exchanged, compared to its average volume of 124,025. The company has a debt-to-equity ratio of 2.94, a current ratio of 0.19 and a quick ratio of 0.16. INVO Bioscience has a fifty-two week low of $0.50 and a fifty-two week high of $7.20. The business’s 50 day moving average is $0.94 and its two-hundred day moving average is $1.03.

INVO Bioscience (NASDAQ:INVO) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $1.58 million during the quarter.

INVO Bioscience Company Profile

INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.